All In Biotech

Drug Trial Radar · NCT03970733

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

ALTERNATIVE SCHEDULE STUDY FOR VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY.

Last checked: Nov 19, 2026Latest source record: Apr 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 246 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

246

Actual

Start

Jul 1, 2019

Primary completion

Apr 7, 2020

Study completion Mar 28, 2022

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Valneva Austria GmbH
First posted
May 31, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In the Main Study Phase a total of 246 subjects were randomized 2:2:1 into three treatment groups to receive either VLA15 with Alum (lower or higher dose) or Placebo. Main Study Phase vaccinations were administered as intramuscular injections on Day 1, Day 57 and Day 180. In the Booster Phase subjects from the higher dose group who completed their primary immunization schedule according to protocol will be randomized 2:1 to receive an additional higher dose VLA15 vaccination or Placebo at Month 18. Study duration in the Main Study Phase per subject is a maximum of 20 months. Overall study Duration is estimated to be 22 months. Study duration per subject in the Booster Phase is a maximum of approximately 13 months. Study duration per subject in the Main Study Phase and Booster Phase together is estimated to be a maximum of approximately 33 months. Overall study duration (i.e., First-Subject-In to Last-Subject Out/ end of Booster Phase) is estimated to be approximately 37 months.

Conditions

  • Lyme Borreliosis

Interventions

  • VLA15Biological

    a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate

  • PlaceboBiological

    PBS (Phosphate Buffered Saline)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GMTs for IgG Against Each OspA SerotypeTime frame: Day 208 (Month 7)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Consulting, LLC

    Milford, Connecticut

  • Stamford Therapeutics Consortium

    Stamford, Connecticut

  • United Medical Associates

    Binghamton, New York

  • Regional Clinical Research, Inc

    Endwell, New York

  • Rochester Clinical Research, Inc.

    Rochester, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.